News Sentiment

HALO sentiment intelligence

Halozyme Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 62 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 77.81 Week of 17 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+2.1% over one week, +13.5% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Is Halozyme ENHANZE Deal Reshaping Subcutaneous Antibody Delivery For Incyte’s Pipeline Strategy (INCY)?

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction 2.1% Price confirming higher
Trend fit Trend active 13.5% over four weeks
Fair value 40.5% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 25
Neutral 33
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
TradingView 8
simplywall.st 6
Quartr 5
Stock Titan 5
Investing.com Canada 3
Sahm 3
Investing.com 3

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 18
Deals and strategy 7
Analyst action 4
Regulatory and legal 2
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 62
Investing.com Canada Direct company coverage

Benchmark reiterates Halozyme stock Buy rating on Incyte deal By Investing.com

Benchmark reiterated its Buy rating and $90 price target for Halozyme Therapeutics following the company's licensing agreement with Incyte Pharmaceuticals. The deal involves Halozyme's Enhanze drug development technology to create subcutaneous formulations of Incyte's INCA033989.

Tone
Neutral 50/100
Event
Analyst action
Published
21 Jul 2026 14:10
Source
Investing.com Canada
Simply Wall Street Direct company coverage

Halozyme Therapeutics (HALO) Lands Incyte Deal On A Valuation That Still Looks Undervalued

Halozyme Therapeutics recently partnered with Incyte, using its Enhanze technology for subcutaneous formulations. Despite a 12.46% share price increase over 30 days and long-term gains, the stock appears undervalued, with analysts estimating a fair value of $83.90 compared to its

Tone
Positive 77/100
Event
Deals and strategy
Published
21 Jul 2026 10:10
Source
Simply Wall Street
Market source Direct company coverage

Halozyme Signs ENHANZE Collaboration with Incyte for Subcutaneous INCA033989 Development

Halozyme Therapeutics has entered into a global collaboration and license agreement with Incyte to develop subcutaneous formulations of INCA033989 using its ENHANZE drug delivery technology. This agreement provides Halozyme with an upfront payment, potential milestone payments, a

Tone
Positive 72/100
Event
Market update
Published
20 Jul 2026 14:41
Source
Market source
Investing.com Canada Direct company coverage

Halozyme partners with Incyte on drug delivery technology By Investing.com

Halozyme Therapeutics Inc. has announced a global collaboration and license agreement with Incyte to develop subcutaneous formulations of INCA033989 using Halozyme's ENHANZE drug delivery technology. Halozyme will receive an upfront payment and is eligible for additional mileston

Tone
Positive 72/100
Event
Market update
Published
20 Jul 2026 12:41
Source
Investing.com Canada
PR Newswire Direct company coverage

Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology

Halozyme Therapeutics, Inc. (Nasdaq: HALO) has entered into a global collaboration and license agreement with Incyte (Nasdaq: INCY) to develop subcutaneous formulations of INCA033989 using Halozyme's ENHANZE® drug delivery technology. This collaboration aims to improve the treatm

Tone
Positive 72/100
Event
Market update
Published
20 Jul 2026 11:41
Source
PR Newswire
Stock Traders Daily Direct company coverage

Technical Reactions to HALO Trends in Macro Strategies

This article from Stock Traders Daily discusses technical reactions to HALO trends in macro strategies, focusing on Halozyme Therapeutics Inc. (NASDAQ: HALO). It highlights conflicting sentiment across different time horizons, suggesting choppy market conditions for the stock. Th

Tone
Negative 36/100
Event
Market update
Published
19 Jul 2026 04:13
Source
Stock Traders Daily
Sahm Direct company coverage

Halozyme Therapeutics (HALO) Gets A Lift As Darzalex Faspro Trial Improves Survival

Halozyme Therapeutics (HALO) saw a positive impact from a partner trial for Darzalex Faspro, which uses Halozyme's ENHANZE technology. The trial reported significant survival benefits for multiple myeloma patients, highlighting the value of ENHANZE in improving established cancer

Tone
Positive 74/100
Event
Market update
Published
18 Jul 2026 19:41
Source
Sahm
TradingView Direct company coverage

ETFs Investing in Halozyme Therapeutics, Inc. Stocks

This article lists various ETFs that include Halozyme Therapeutics, Inc. (HALO) stocks in their portfolios. The ETFs are sorted by their market value and provide details like weight, issuer, management style, expense ratio, and AUM, making it easier for investors to find opportun

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 17:41
Source
TradingView
TradingView Direct company coverage

HALO5387960 Bond Risk Profile

This article provides a risk profile for the Halozyme Therapeutics, Inc. 0.25% 01-MAR-2027 bond, identified as HALO5387960. It offers an overview of the bond's coupon, redemption details, and crucial risk assessment metrics. The content highlights credit risk, security level, inf

Tone
Neutral 50/100
Event
Balance sheet
Published
15 Jul 2026 06:12
Source
TradingView
TradingView Direct company coverage

HALO5387960 Bond Coupon Profile — Rate & Payments

This article provides a coupon profile for the HALO5387960 bond, issued by Halozyme Therapeutics, Inc., detailing its interest rate and payment schedule. The bond has a current coupon rate of 0.25%, with the next payment planned for September 1, 2026. The article highlights the i

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 22:40
Source
TradingView
TradingView Direct company coverage

HALO5387960 Bond Profile — Key Metrics

This article provides a bond profile for Halozyme Therapeutics, Inc.'s bond HALO5387960, detailing key metrics such as its 0.25% coupon rate and March 1, 2027 maturity date. It also includes information about the company, Halozyme Therapeutics, Inc., identifying it as a biopharma

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 14:41
Source
TradingView
Quartr Direct company coverage

Halozyme Therapeutics (HALO) Proxy filing Summary

Halozyme Therapeutics (HALO) has released a summary of its proxy filing for the 2026 Annual Meeting, scheduled virtually for May 5, 2026. Key proposals include the election of two Class I directors, an advisory "say-on-pay" vote for executive compensation, and the ratification of

Tone
Positive 74/100
Event
Market update
Published
12 Jul 2026 04:40
Source
Quartr
Quartr Direct company coverage

Halozyme Therapeutics (HALO) AGM 2026 Summary

This article summarizes Halozyme Therapeutics' (HALO) 2026 Annual General Meeting (AGM), detailing the election of Class I directors, approval of executive compensation, and ratification of Ernst & Young LLP as the independent auditor. It also provides a brief overview of recent

Tone
Positive 72/100
Event
Regulatory and legal
Published
11 Jul 2026 18:11
Source
Quartr
Quartr Direct company coverage

Halozyme Therapeutics (HALO) Q1 2026 earnings summary

Halozyme Therapeutics reported a strong Q1 2026 with total revenue increasing by 42% year-over-year to $376.7 million and net income up 27% to $150 million. The company announced a new $1 billion share repurchase program and expanded its ENHANZE and Hypercon platforms through new

Tone
Positive 93/100
Event
Earnings
Published
11 Jul 2026 16:41
Source
Quartr
Quartr Direct company coverage

Halozyme Therapeutics (HALO) Q1 2025 earnings summary

Halozyme Therapeutics reported a strong Q1 2025, achieving 35% year-over-year revenue growth to $265 million and a 54% increase in net income to $118 million, driven by blockbuster products and new growth catalysts. The company also announced a $250 million share repurchase progr

Tone
Positive 93/100
Event
Earnings
Published
11 Jul 2026 08:39
Source
Quartr
TradingView Direct company coverage

Halozyme Therapeutics, Inc. Stock 12‑Month Price Target Cut to $83.44, Implies 6% Upside

Halozyme Therapeutics, Inc.'s average price target has been reduced from $83.9 to $83.44 by 9 analysts, with forecasts ranging from $57 to $96 per share. This new target implies a potential upside of approximately 6% based on the July 9 closing price. Despite the slight reduction

Tone
Positive 59/100
Event
Analyst action
Published
10 Jul 2026 07:11
Source
TradingView
TradingView Direct company coverage

2 Reasons to Like HALO and 1 to Stay Skeptical

Halozyme Therapeutics (HALO) shows strong potential with impressive annualized revenue growth of 35.4% over five years and an excellent free cash flow margin averaging 46.2%. However, its adjusted operating margin significantly decreased by 35.1 percentage points in the last five

Tone
Positive 59/100
Event
Earnings
Published
10 Jul 2026 04:11
Source
TradingView
Sahm Direct company coverage

How Halozyme’s Leadership Shake-Up Around Drug Delivery At Halozyme Therapeutics (HALO) Has Changed Its Investment Story

Halozyme Therapeutics recently restructured its leadership, appointing David Ramsay as President of Drug Delivery and announcing the departure of COO Cortney Caudill. This move emphasizes the company's focus on its drug delivery franchise, particularly the ENHANZE platform, and a

Tone
Positive 64/100
Event
Market update
Published
10 Jul 2026 04:10
Source
Sahm